FEATURES OF PRIMARY AND ADAPTIVE IMMUNOTHERAPY RESISTANCE IN MICROSATELLITE INSTABLE CANCERS - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.

¿Cuál es la Condición que se está estudiando?

Stage III unresectable colorectal cancer or stage IV endometrial, prostate, or gastrointestinal cancer

¿Quién puede participar en el Estudio?

Adults ages 18 and older who:

Are diagnosed with stage III or IV endometrial, prostate, hepatobiliary, pancreatic, and gastrointestinal cancers with certain tumor mutations
Do not have prostate tumors with small cell component
Are not pregnant or breastfeeding

Grupo etario

Adultos

¿Qué Implica?

Si elige unirse a este estudio, podrá:

Go through a screening period to see if you're eligible for the study
Start participating before, during, or after treatment with standard of care immunotherapy for your cancer

If you're eligible to join, you will be monitored until you complete your immunotherapy treatment and the final blood and/or tissue samples are collected.

During this monitoring period, we will collect the following from you: